Optomed Oyj Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Juho Himberg

İcra Kurulu Başkanı

€64.0k

Toplam tazminat

CEO maaş yüzdesi	81.3%
CEO görev süresi	1.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Sep 27

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

May 11

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

May 10

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Mar 22

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Feb 18

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Dec 21

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Nov 15

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Aug 09

CEO Tazminat Analizi

Juho Himberg'un ücretlendirmesi Optomed Oyj'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-€6m
Jun 30 2024	n/a	n/a	-€5m
Mar 31 2024	n/a	n/a	-€4m
Dec 31 2023	€64k	€52k	-€4m

Tazminat ve Piyasa: Juho 'nin toplam tazminatı ($USD 67.05K ), Finnish pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 322.63K ).

Tazminat ve Kazançlar: Juho şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Juho Himberg (54 yo)

1.1yrs

Görev süresi

€64,000

Tazminat

Mr. Juho Himberg is Chief Executive Officer of Optomed Oyj since October 1, 2023. He has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Juho Himberg	Chief Executive Officer	1.1yrs	€64.00k	Veri yok
Seppo Kopsala	Founder	20.8yrs	€156.00k	Veri yok
Sakari Knuutti	CFO, Chief Legal Officer & Secretary of the Board	5.8yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: OPTOMED 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Seppo Makinen	Independent Director	5.8yrs	€19.00k	0.062% € 48.5k
Reijo Tauriainen	Independent Director	5.8yrs	€19.00k	0.078% € 60.7k
Catherine Calarco	Independent Director	1.5yrs	€19.00k	0.017% € 13.5k
Petri Salonen	Chairman of the Board	18.8yrs	€114.00k	0.083% € 64.3k
Ty Lee	Independent Director	1.5yrs	€19.00k	0.017% € 13.5k
Anna Tenstam	Independent Director	4.4yrs	€19.00k	0.037% € 28.6k
Robert Chang	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Nina Hautala	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Dan Milea	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Tunde Peto	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Daniel Ting	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OPTOMED 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Optomed Oyj Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Optomed Oyj, Annual General Meeting, May 09, 2025

Optomed Oyj Announces Nomination Board

Optomed Oyj, Annual General Meeting, May 10, 2024

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

Recent updates

Price target decreased by 9.3% to €5.83

Optomed plc Raises Earnings Guidance for the Full Year 2024

No longer forecast to breakeven

Third quarter 2024 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

No longer forecast to breakeven

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

New minor risk - Market cap size

Optomed Oyj, Annual General Meeting, May 09, 2025

Price target decreased by 8.8% to €6.05

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Reaffirms Revenue Guidance for the Year 2024

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

Price target increased by 14% to €6.63

Forecast to breakeven in 2026

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

First quarter 2024 earnings released: €0.064 loss per share (vs €0.076 loss in 1Q 2023)

New major risk - Share price stability

Optomed Plc Announces Optomed Aurora with AEYE Receives U.S. Food & Drug Administration Clearance in US

Optomed USA, Inc. Introduces Optomed Aurora AEYE

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Consensus estimates of losses per share improve by 15%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 12%

Consensus revenue estimates decrease by 12%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Optomed Oyj Announces Nomination Board

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optomed Oyj Provides Revenue Guidance for the Year 2023

Forecast breakeven date moved forward to 2024

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.290413 million.

Consensus EPS estimates fall by 15%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

New major risk - Share price stability

Optomed Oyj, Annual General Meeting, May 10, 2024

Forecast breakeven date pushed back to 2025

Optomed Announces CEO Transition Plan

Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Optomed Oyj Approves Board Changes

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Optomed Plc Provides Revenue Guidance for the Full Year 2023

Price target decreased by 9.9% to €6.37

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS misses analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year of 2023

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

Consensus EPS estimates fall by 12%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Updates Earnings Guidance for the Full Year 2022

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Optomed Oyj Announces Board Appointments

Optomed plc Elects Mars Duan to the Board of Directors

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Optomed Oyj, Annual General Meeting, May 10, 2023

Optomed Plc Announces Resignation of Xisi Guo from Board of Directors, Effective August 19, 2022

Optomed Oyj Announces Resignation of Niina Huikuri as Vice President, Marketing and Member of the Leadership Team

Optomed Oyj Announces Executive Changes

Optomed Oyj Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.822593 million.

Price target decreased to €8.45

No longer forecast to breakeven

High number of new and inexperienced directors